{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:08:00Z","timestamp":1794917280503,"version":"4.9.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>A close temporal relationship between SSc onset and cancer has been reported in anti-RNA polymerase III-positive patients. We investigated the association between cancer and other SSc autoantibodies in a national SSc registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SSc patients enrolled in the Canadian Scleroderma Research Group registry from 2004 to 2019 were characterized according to autoantibodies to centromere, topoisomerase I\/Scl70, RNA polymerase III, fibrillarin, Th\/To (hPOP1), PM\/Scl, Ku, NOR90, Ro52\/TRIM21 and U1RNP. Logistic regression was used to examine the association between a close cancer-SSc interval and autoantibody status, adjusted for age, sex, race and smoking history.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 1698 SSc patients, 1481 (87%) had available autoantibody data. Cancer was diagnosed within 2, 3 and 5\u2009years of the first non-Raynaud manifestation in 1.3%, 2.1% and 3.5% of patients. The most frequent cancers diagnosed within 2\u2009years were breast (33%), gynaecological (19%) and haematological (14%) cancers. The risk of cancer within 2\u2009years was increased among anti-topoisomerase I [odds ratio (OR) 3.43, 95% CI: 1.04, 10.05] and anti-U1-RNP-positive patients (OR 5.54, 95% CI: 1.16, 20.40), but not with anti-RNA polymerase III. None of the anti-fibrillarin, Th\/To, PM\/Scl, Ku and NOR90-positive patients had cancer within 2\u2009years. Patients with anti-centromere or none of the tested autoantibodies had numerically lower risks of developing cancer within two years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Synchronous cancer was rare in this large cohort of predominantly female and White SSc patients. The risk of cancer within 2\u2009years was increased among anti-topoisomerase I and anti-U1-RNP-positive patients. Screening strategies guided by autoantibodies require further careful consideration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab735","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T20:30:14Z","timestamp":1633033814000},"page":"2905-2914","source":"Crossref","is-referenced-by-count":34,"title":["Association between autoantibodies in systemic sclerosis and cancer in a national registry"],"prefix":"10.1093","volume":"61","author":[{"given":"Sabrina","family":"Hoa","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Montreal"},{"name":"Division of Rheumatology, University of Montreal Hospital Center"},{"name":"University of Montreal Hospital Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Lazizi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-6165","authenticated-orcid":false,"given":"Murray","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University"},{"name":"Division of Rheumatology, Jewish General Hospital"},{"name":"Lady Davis Institute for Medical Research , Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mianbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research , Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1652-6608","authenticated-orcid":false,"given":"Marvin J","family":"Fritzler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cumming School of Medicine, University of Calgary , Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University"},{"name":"Division of Rheumatology, Jewish General Hospital"},{"name":"Lady Davis Institute for Medical Research , Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Canadian Scleroderma Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,2]]},"reference":[{"key":"2022070614084088000_keab735-B1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022070614084088000_keab735-B2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatology"},{"key":"2022070614084088000_keab735-B3","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022070614084088000_keab735-B4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5301\/jsrd.5000250","article-title":"Mechanistic and clinical insights at the scleroderma-cancer interface","volume":"2","author":"Shah","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2022070614084088000_keab735-B5","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022070614084088000_keab735-B6","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022070614084088000_keab735-B7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3899\/jrheum.101144","article-title":"Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies","volume":"38","author":"Airo","year":"2011","journal-title":"J Rheumatol"},{"key":"2022070614084088000_keab735-B8","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2022070614084088000_keab735-B9","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022070614084088000_keab735-B10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"2022070614084088000_keab735-B11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/BOR.0000000000000222","article-title":"Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening","volume":"27","author":"Shah","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2022070614084088000_keab735-B12","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.40065","article-title":"Brief Report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma","volume":"69","author":"Shah","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022070614084088000_keab735-B13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2022070614084088000_keab735-B14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/rheumatology\/kew382","article-title":"Resolution of paraneoplastic PM\/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour","volume":"56","author":"Bruni","year":"2017","journal-title":"Rheumatology"},{"key":"2022070614084088000_keab735-B15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.22451","article-title":"2013 American College of Rheumatology\/European League Against Rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group","volume":"67","author":"Alhajeri","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2022070614084088000_keab735-B16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022070614084088000_keab735-B17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2022070614084088000_keab735-B18","first-page":"458","article-title":"Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization","volume":"35","author":"Hsu","year":"2008","journal-title":"J Rheumatol"},{"key":"2022070614084088000_keab735-B19","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.40893","article-title":"Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma","volume":"71","author":"Shah","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022070614084088000_keab735-B20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","article-title":"Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature","volume":"13","author":"Colaci","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2022070614084088000_keab735-B21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s10067-004-0940-5","article-title":"Association between systemic sclerosis and breast cancer: eight new cases and review of the literature","volume":"23","author":"Launay","year":"2004","journal-title":"Clin Rheumatol"},{"key":"2022070614084088000_keab735-B22","first-page":"1179","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022070614084088000_keab735-B23","first-page":"539","article-title":"Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy","volume":"54","author":"Husain","year":"1994","journal-title":"Cancer Res"},{"key":"2022070614084088000_keab735-B24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.1780390423","article-title":"Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases","volume":"39","author":"Kuwana","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2022070614084088000_keab735-B25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.41493","article-title":"Cancer in systemic sclerosis: analysis of antibodies against components of the Th\/To complex","volume":"73","author":"Mecoli","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022070614084088000_keab735-B26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.canep.2013.04.014","article-title":"The risk of cancer development in systemic sclerosis: a meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"2022070614084088000_keab735-B27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/jcm9030853","article-title":"Biphasic temporal relationship between cancers and systemic sclerosis: a clinical series from Montpellier University Hospital and review of the literature","volume":"9","author":"Partouche","year":"2020","journal-title":"J Clin Med"},{"key":"2022070614084088000_keab735-B28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/2397198318766825","article-title":"Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: longitudinal data from the Canadian Scleroderma Research Group","volume":"3","author":"Sakr","year":"2018","journal-title":"J Scleroderma Relat Disord"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab735\/40785884\/keab735.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/7\/2905\/44473327\/keab735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/7\/2905\/44473327\/keab735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T14:13:29Z","timestamp":1657116809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/7\/2905\/6380442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,2]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,10,2]]},"published-print":{"date-parts":[[2022,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab735","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,10,2]]}}}